Crohn's & Colitis UK
Guide
For patients
A guide to ustekinumab, an interleukin inhibitor that blocks IL-12 and IL-23. Stelara was the first brand and several biosimilars now exist. The first dose is a drip, then injections under the skin; the page covers trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
interleukin inhibitor
IL-12
IL-23
biosimilar
Cochrane
Systematic review
May 2025
Patients and professionals
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics
Biologics and newer medicines
Jargon explained
IL-12/23
induction
certainty of evidence
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy
New England Journal of Medicine
Study
Nov 2016
Patients and professionals
The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.
Topics
Biologics and newer medicines
Jargon explained
induction
maintenance
IL-12/23
placebo
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF
The Lancet
Study
Jun 2022
Patients and professionals
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics
Biologics and newer medicines
Research
Jargon explained
head-to-head trial
biologic-naive
confidence interval
Royal Free London NHS Foundation Trust
Leaflet
Aug 2025
For patients
A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.
Topics
Biologics and newer medicines
Jargon explained
biologic
infusion
biosimilar
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
NICE
Guideline
May 2023
For professionals
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
biological treatment
NICE
Guideline
Jul 2025
For professionals
NICE's appraisal allowing mirikizumab (Omvoh) to be used for adults with moderate to severe Crohn's disease after a previous biologic has not worked or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
NICE
Guideline
Aug 2025
For professionals
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
conventional treatment
Crohn's & Colitis UK
Guide
Dec 2025
For patients
A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.
Topics
Biologics and newer medicines
Jargon explained
IL-23
interleukin inhibitor